# Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option

> **NCT02094443** · PHASE2 · COMPLETED · sponsor: **Debiopharm International SA** · enrollment: 52 (actual)

## Conditions studied

- Hepatitis C
- Liver Disease

## Interventions

- **DRUG:** Alisporivir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT02094443
- **Lead sponsor:** Debiopharm International SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02094443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02094443, "Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02094443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*